It doesn't take two: The Tipline for 18 June 2019
As the healthcare industry remains under scrutiny in the US, Pfizer has marched ahead with an $11 billion merger that could reshape the cancer treatment landscape. Meanwhile, a US senator is calling on Congress to reorganise civil antitrust enforcement so that it is done under one roof and not split between two authorities.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10